CytoDel is a pioneering brand that focuses on addressing high-value medical needs through their patented and proprietary platform. Founded to commercialize technology developed at the renowned NYU-Grossman School of Medicine, CytoDel holds an exclusive license from NYU for their innovative platform. CytoDel utilizes recombinant protein engineering to produce atoxic rBoT derivatives, which retain the intraneuronal trafficking properties of native botulinum toxin (BoT).

These derivatives have a controllable safety profile customized to specific medical indications. Their lead program offers a groundbreaking solution by completely inactivating the protease responsible for the toxicity of native BoT. This enables the use of rBoTs for delivering therapeutic proteins to the cytoplasm of neurons.

CytoDel's approach shows great promise for treating conditions with high unmet medical needs in both the peripheral and central nervous system. With a strong focus on innovation and scientific excellence, CytoDel is at the forefront of revolutionizing the field of medical treatments. For more information about their groundbreaking technology, visit their official website